Apple's legal battle over watch patents

Customers are experiencing the newly launched iPhone 15 at Apple's flagship store in Shanghai, China, on September 24, 2023. (Photo by Costfoto/NurPhoto via Getty Images)
Customers are experiencing the newly launched iPhone 15 at Apple's flagship store in Shanghai, China, on September 24, 2023. (Photo by Costfoto/NurPhoto via Getty Images)
Images source: © GETTY | NurPhoto

6:05 AM EST, January 18, 2024

Apple's response to the ban

In the ongoing patent dispute involving Apple and medical technology company Masimo, Apple has announced it will disable the blood oxygen monitoring feature in two of its flagship Apple Watch models - Series 9 and Ultra 2 - in the United States. This decision comes after a U.S. Court of Appeals ruling that reinstated a sales ban on these models, pending Apple's appeal against an earlier ban imposed by the U.S. International Trade Commission (ITC)​​​​.

The legal battle, potentially lasting up to a year, revolves around patents held by Masimo, which accuses Apple of infringing on its pulse oximetry technology. This technology is crucial for the blood oxygen monitoring feature in the Apple Watches. Apple has countered these allegations, expressing strong disagreement with the ITC's decision and emphasizing its commitment to challenging the ruling. The company has already removed these watch models from its website and stores in response to the ban, which initially went into effect in December 2023​​​​.

Market impact and Apple's alternatives

The exclusion of the blood oxygen feature in the U.S. market is a significant move for Apple, given that the Apple Watch is a major player in the global smartwatch market, accounting for about a quarter of it. Despite this setback, Apple's overall revenue from its wearables, home, and accessory business, which includes the Apple Watch, remains substantial, bringing in $8.28 billion in revenue in the third quarter of 2023 alone​​.

However, the Series 9 and Ultra 2 models will continue to be available for sale without the disputed feature. They will still display the app icon for the blood oxygen features, but users will be informed that the feature is unavailable upon tapping. This strategy allows Apple to maintain its presence in the smartwatch market while complying with the legal constraints​​​​.

Broader implications and future outlook

This case highlights the intricate dynamics of intellectual property rights in the technology sector, where even large companies like Apple are not immune to patent disputes. The outcome of this legal battle could have broader implications for the industry, particularly concerning how tech companies navigate patent laws and innovate without infringing on existing patents.

As the case progresses, Apple remains determined to overturn the ITC's decision, arguing that the ban could harm the company, its suppliers, and the public. The legal proceedings and appeals process will continue over the coming months, keeping stakeholders and consumers closely watching for developments​​​​.

In summary, this dispute underscores the delicate balance between protecting intellectual property and fostering innovation in the fast-paced world of technology. The final resolution of this case will be closely watched, as it could set important precedents for future patent disputes in the tech industry.